Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MUSE therapy: preliminary clinical observations

P Werthman1, J Rajfer

  • 1Department of Urology, University of California at Los Angeles School of Medicine 90095-1738, USA.

Urology
|December 31, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The two phases of the clinical validation of preclinical translational mechanistic research on PDE5 inhibitors since Viagra's advent. A personal perspective.

International journal of impotence research·2018
Same author

Myostatin, a profibrotic factor and the main inhibitor of striated muscle mass, is present in the penile and vascular smooth muscle.

International journal of impotence research·2017
Same author

Oral Bisphenol A (BPA) given to rats at moderate doses is associated with erectile dysfunction, cavernosal lipofibrosis and alterations of global gene transcription.

International journal of impotence research·2013
Same author

Early onset erectile dysfunction is usually not associated with abnormal cavernosal arterial Inflow.

International journal of impotence research·2013
Same author

Discovery of NO in the penis.

International journal of impotence research·2008
Same author

Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats.

International journal of impotence research·2007

Intracavernosal injections are more effective for erectile dysfunction than the transurethral alprostadil system (MUSE). MUSE resulted in fewer rigid erections and more side effects compared to injections.

Area of Science:

  • Urology
  • Pharmacotherapy
  • Sexual Medicine

Background:

  • Intracavernosal injections of vasodilators are a primary treatment for erectile dysfunction.
  • A transurethral delivery system for alprostadil (MUSE) offers an alternative pharmacotherapy approach.

Purpose of the Study:

  • To compare the efficacy and safety of MUSE with intracavernosal injections for erectile dysfunction.

Main Methods:

  • One hundred men with erectile dysfunction were treated with MUSE (125–1000 micrograms).
  • Patients had prior experience with intracavernosal injections (papavarine, Regitine, prostaglandin E1).
  • Erection quality and adverse events were assessed clinically.

Main Results:

  • MUSE achieved rigid erections in 7% of patients, with 30% experiencing partial rigidity.

Related Experiment Videos

  • Intracavernosal injections yielded sustained rigid erections in 49% of patients.
  • Adverse events with MUSE included pain (24%), syncope (3%), urethral bleeding (3%), and priapism (1%).

    • Conclusions:

    • Intracavernosal injections demonstrate superior effectiveness in achieving rigid erections compared to MUSE.
    • MUSE is less effective and associated with a higher incidence of adverse events for erectile dysfunction treatment.